Cereton, 250 mg/ml 4 ml 3 pcs

Pharmacodynamics

Cereton provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation.

It increases linear velocity of blood flow on the side of the traumatic brain injury, promotes normalization of spontaneous bioelectrical activity of the brain, regress of focal neurological symptoms and restoration of consciousness; it has a positive effect on cognitive and behavioral responses of patients with cerebral vascular diseases (discirculatory encephalopathy and residual effects of brain circulation disorders). Stimulates dose-dependent release of acetylcholine under physiological conditions, improves synaptic transmission and receptor function. It does not influence the reproductive cycle and has no teratogenic and mutagenic action.

It has preventive and corrective action on pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes: participates in the synthesis of phosphatidylcholine (membrane phospholipid) and improves neuronal membrane plasticity.

Pharmacokinetics

When administered parenterally (10 mg/kg) Cereton mainly accumulates in the brain, lungs and liver. Absorption is 88%, easily penetrates through the blood-brain barrier (when administered orally, the concentration in the brain is 45% of that in plasma). The lungs excrete 85% of the drug as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Indications

Acute and recovery periods of severe TBI and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;

Pharmacological effect

Pharmacodynamics

Cereton ensures the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, and activates the reticular formation.

Increases the linear speed of blood flow on the side of traumatic brain injury, promotes the normalization of spatiotemporal characteristics: spontaneous bioelectrical activity of the brain, regression of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral reactions of patients with vascular diseases of the brain (dyscirculatory encephalopathy and residual effects of cerebrovascular accident). Stimulates the dose-dependent release of acetylcholine under physiological conditions, improves synaptic transmission and receptor function. Does not affect the reproductive cycle and does not have a teratogenic or mutagenic effect.

It has a preventive and corrective effect on the pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes: participates in the synthesis of phosphatidylcholine (membrane phospholipid), improves the plasticity of neuronal membranes.

Pharmacokinetics

When administered parenterally (10 mg/kg), Cereton predominantly accumulates in the brain, lungs and liver. Absorption – 88%, easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45% of that in plasma). The lungs excrete 85% of the drug in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Special instructions

Cereton does not affect the speed of psychomotor reactions.

Active ingredient

Choline alphoscerate

Composition

1 ml contains:

active substance:

glycerylphosphorylcholine hydrate 250 mg,

excipients:

water for injections

Pregnancy

Contraindicated during pregnancy and breastfeeding.

Contraindications

pregnancy; breastfeeding period;
children under 18 years of age (due to lack of data).
hypersensitivity to the drug;
acute stage of hemorrhagic stroke;

Side Effects

Nausea may occur (mainly as a consequence of dopaminergic activation), in which case the dose of the drug is reduced.

From the digestive system: constipation, diarrhea, dry oral mucosa, pharyngitis.

From the nervous system: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, convulsions, dizziness.

From the skin: rash, urticaria.

Other: pain at the injection site, increased urination.

Allergic reactions.

Interaction

No significant interactions with other drugs have been identified.

Overdose

Symptoms: Nausea may occur.

Treatment: symptomatic therapy.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C

Shelf life

5 years

Manufacturer

PharmFirma Sotex, Russia